What Public Health Vaccines does

Public Health Vaccines is a privately held, early-stage vaccine development company based in Cambridge, Massachusetts, focused on countermeasures against emerging infectious diseases, with an emphasis on filoviruses for which no licensed vaccines currently exist. The company's portfolio comprises two early-stage vaccine candidates: a Bundibugyo ebolavirus candidate built on the recombinant vesicular stomatitis virus (rVSV) platform — the same technology employed in an already-licensed Ebola vaccine — and a Marburg virus vaccine designated PHV01.

Operationally, Public Health Vaccines is a small team of 1-10 employees that builds its pipeline through institutional partnerships rather than a captive commercial infrastructure. It has secured a $1.9 million grant from the Coalition for Epidemic Preparedness Innovations (CEPI) to generate Master Viral Seed stock for the Bundibugyo candidate, placing it within a broader $50 million CEPI portfolio of four Bundibugyo vaccine candidates (alongside IAVI, Moderna, and University of Oxford/Serum Institute of India, with BARDA co-funding). For the Marburg program, the company is partnered with Institut Pasteur de Dakar to develop and manufacture PHV01 at IPD's MADIBA facility in Senegal, enabling African production for resource-limited outbreak settings.

The business model is grant- and partnership-funded R&D: revenue recognition is not applicable at this stage, pricing is not publicly disclosed, and end customers — African public health authorities and government agencies in the Democratic Republic of Congo and Uganda — would ultimately procure through international mechanisms such as CEPI, Gavi, and WHO rather than direct commercial channels. The near-term value-creation lever is advancement of candidates into clinical testing and the establishment of sustainable manufacturing capacity in outbreak-prone regions.

Name

Public Health Vaccines

Website

https://phvaccines.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Public Health Vaccines is a privately held, Cambridge-based biotech developing early-stage vaccine candidates against outbreak pathogens — including Bundibugyo ebolavirus and Marburg virus — for African public health authorities and international procurement agencies, funded primarily by CEPI grants and partnered with Institut Pasteur de Dakar for African manufacturing.

Ownership category

akta.pro rank

Product category

Infectious Disease Vaccines

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC)

akta.pro secondary industry

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

Keywords

• Infectious disease vaccines
• Ebola vaccine development
• Marburg virus vaccine
• Recombinant viral vaccine platform
• Outbreak preparedness vaccines

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Supply Chain

Core offering

Public Health Vaccines develops investigational vaccine candidates against outbreak-prone filoviruses, specifically a Bundibugyo ebolavirus vaccine built on the recombinant vesicular stomatitis virus (rVSV) platform and a Marburg virus vaccine (PHV01). The company operates at the early/pre-clinical stage, advancing candidates through grant-funded research and strategic manufacturing partnerships aimed at outbreak preparedness in resource-limited African settings.

Product overview

Public Health Vaccines is a vaccine development company focused on countermeasures against emerging infectious diseases, particularly filoviruses. The company's portfolio includes a Bundibugyo ebolavirus vaccine candidate using the recombinant vesicular stomatitis virus platform (in early-stage development with CEPI funding), and a Marburg virus vaccine (PHV01) being developed in partnership with Institut Pasteur de Dakar for African manufacturing at the MADIBA facility. The company is advancing investigational vaccines without licensed options currently available against these pathogens.

Differentiator

Problem solved

Functional benefit

Products and services

• Bundibugyo Ebolavirus Vaccine Candidate An investigational vaccine candidate against the Bundibugyo ebolavirus, built on the recombinant vesicular stomatitis virus (rVSV) platform used in an already licensed Ebola vaccine. Currently in early-stage development and advancing toward clinical testing with CEPI grant funding, targeting outbreak response where no licensed vaccines currently exist.
• Marburg Virus Vaccine (PHV01) A Marburg virus vaccine candidate developed through strategic partnership with Institut Pasteur de Dakar to enable local African manufacturing at the MADIBA facility, with the goal of making the vaccine accessible in resource-limited outbreak settings across the African continent.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Institut Pasteur de DakarcoreStrategic or Co-development Partner · 18 December 2025Strategic partnership to develop and manufacture Marburg virus vaccine (PHV01) in Africa. The partnership enables local production at IPD's MADIBA (Manufacturing Africa for DiCE) facility and aims to make the vaccine accessible in resource-limited settings across the African continent.

Scale indicators3 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• IAVI: Non-profit product developer and one of the four CEPI-funded Bundibugyo ebolavirus vaccine developers alongside Public Health Vaccines, using a different technology platform but competing head-to-head for the same CEPI milestones and stockpile procurement.
• University of Oxford / Serum Institute of India: Oxford's Jenner Institute and SII are the fourth CEPI-funded Bundibugyo vaccine developer; comparable in that they target the same pathogen and procurement channels, but vastly better resourced and with existing large-scale manufacturing capacity through SII.
• Sabin Vaccine Institute: Non-profit advancing a Marburg virus vaccine candidate with similar mission-driven, outbreak-response positioning; comparable target pathogen and global-health funding model, making Sabin a direct emerging peer in the Marburg space.

Broad incumbents

• Moderna: mRNA platform leader and another of the four CEPI-funded Bundibugyo vaccine developers; competes with Public Health Vaccines on the same Bundibugyo program while bringing far greater capital, clinical infrastructure, and pandemic-vaccine experience.
• Merck (Ervebo): Merck's Ervebo is the licensed rVSV-based Ebola Zaire vaccine on which Public Health Vaccines' platform is modeled; directly comparable technology and target family, though Ervebo does not cover the Bundibugyo strain that PHV's candidate addresses.
• Janssen (Johnson & Johnson): Janssen developed the Zabdeno/Mvabea two-dose Ebola vaccine regimen; a broad-incumbent filovirus competitor already supplying stockpile procurement channels that Public Health Vaccines would also need to access for outbreak response.
• Bavarian Nordic: Vaccine company with established biodefense and outbreak-vaccine franchises including MVA-BN-based platforms; relevant peer for valuation and procurement-channel comparison as a listed infectious-disease vaccine developer in adjacent indications.
• Emergent BioSolutions: Specialty biodefense vaccine developer with US government contracts and stockpile relationships; comparable in customer mix (BARDA, HHS) and outbreak-preparedness mission, though focused on different pathogens.
• BioNTech: mRNA vaccine leader co-developing Ebola and other infectious-disease candidates with pandemic-preparedness funders; comparable in technology-class ambition for outbreak vaccines but operating at vastly greater scale and capital base.

Others

• Institut Pasteur de Dakar: Strategic manufacturing partner via the MADIBA facility but also an independent African vaccine developer; comparable as a regional player shaping African vaccine manufacturing and outbreak-response supply chains relevant to PHV's go-to-market.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Public Health Vaccines